Sébastien Wieckowski, Ph.D.

Immuno-oncologist, age 44, French/EU, married and one child

Education

Ph.D. in Immunology

Université Louis Pasteur Strasbourg, France
2007

M.Sc. in Health Biology (DEA Biologie Santé)

Université Montpellier II, France
2003

Maîtrise in Biochemistry + Organic Chemistry

Université Montpellier II, France
2002

B.Sc. in Biochemistry + Bioinformatics (summa cum laude)

Université Montpellier II, France
2001

Languages

  • French (native)
  • English (professional)
  • German (elementary; currently updating)
  • Polish (elementary)

Interests

  • Retrogaming
  • Electronics
  • Ethical hacking
  • DIY and gardening
  • Half-marathon
  • Tennis
  • Hiking

Profile summary

  • Highly accomplished immunologist with a PhD, specializing in immuno-oncology and cancer vaccine development for over 15 years in the biotechnology sector
  • Experience in all phases of drug development, including early discovery, IND-enabling preclinical studies, GLP nonclinical and biomarker support for phase II trials, and GMP bioassays for phase III studies and drug commercialization
  • Demonstrated research impact (h-index 18) with 6 first-authored and 18 co-authored publications in high-impact journals, and actively contributing to scientific progress with 2 international patents and involvement in the review process for numerous journals
  • Resourceful scientist with expertise in immunology techniques, animal models, and molecular biology; leverages data analysis and bioinformatics to solve complex problems, and readily embraces new technologies like AI to drive discovery
  • Provided technical leadership for various platforms, guiding and mentoring technicians, students, and PhD candidates

R&D experience

Data Analyst Biotech/Pharma Freelance

2023 — present
second scight (Strasbourg, France)
second scight
  • Analysis of experimental data (high-throughput bioassays, flow cytometry, animal experiments), reports and interactive dashboards
  • Strong input for non-clinical regulatory dossiers (strategy, data analysis, text and figures)
  • Complete, appropriate and easy to understand biostatistical reports
  • (sc)RNA-Seq analysis of client's data or public databases, vaccine design, and more bioinformatics
  • Due diligence objectively and truthfully examining raw data
  • Writing entire scientific articles, and designing slides and posters for technical, scientific and business presentations
  • Additional à la carte services such as teaching good practices in data management and analysis, setup of a good software stack
data analysis flow cytometry bioassays animal experiments nonclinical regulatory biostatistics bioinformatics RNA-Seq vaccine due diligence scientific writing

Director Nonclinical Development

2021 — 2023
Worg Pharmaceuticals, Allschwil (CH) / Hangzhou (CN)
  • Development of the preclinical program for our drug candidates
    • in vitro and in vivo pharmacology, pharmacokinetics and toxicology
    • IND-enabling GLP program from scratch for a small molecule in ophthalmology
    • Extension of non-clinical package for supporting a Phase 2a clinical trial
  • EMA, FDA and CDE (China) regulatory documents: pre-IND Briefing Package, Investigator Brochure, CTD (Module 2.4), IND application
  • Management of all the preclinical operations with CROs
GLP pharmacology toxicology nonclinical PK/PD ocular toxicity juvenile toxicology DART nonhuman primates ICH guidelines FDA EMA CDE (China) IND CTD PIND Graves' Disease allergy small molecules peptides

Principal Scientist

2018 — 2021
University of Applied Sciences (FHNW) / Roche, Basel, Switzerland
  • Development of innovative bioassays in immunology and cell and gene therapy (GMP)
  • Training of the technical staff in flow cytometry, and human cell biology/immunology
  • Scientific and technical support in many projects
GMP ddPCR imaging cytometry multiplex RNAseq NK cells macrophages ADCC ADCP gene therapy AAV Pentraxin-2 gantenerumab pertuzumab glofitamab

Senior Scientist (part-time consulting)

2020 — 2021
NEC / VAXIMM AG, Basel, Switzerland
  • Responsible for the personalized neoantigen vaccine assembly for the clinical trial NECVAXNEO1
personalised medicine DNA vaccine glioblastoma NGS neoantigen discovery epitope assembly machine learning

Senior Scientist

2016 — 2018
VAXIMM GmbH, Mannheim, Germany
  • R&D and nonclinical development of the company’s oral T cell vaccine pipeline – VXM01, VXM04, VXM06, VXM10 and VXMNeo
  • Supervision of the immunomonitoring and histopathology GCLP analyses of our phase I/II clinical trials
  • Business Development (industry, academic collaborations) and interaction with CRO partners
  • Regular and active participation to our Company Board and internal meetings + international congresses
DNA vaccine preclinical toxicology angiogenesis CROs histology bioinformatics data science business development Investigator Brochure

Parental Leave

2015
Alsace, France
  • Provision of care for my baby
  • Completion of a full renovation of a house within budget (coordination and scheduling of the activities of 10+ contractors, partnering with local community members to gain planning approvals, taking lessons to gain specific technical skills in plumbing, electricity, carpentry, floors and painting)
  • Updating and extending professional skills in physiology, biostatistics, and programming
becoming a Great Dad construction work biostatistics Python 3

Roche Postdoc Fellowship (RPF)

2012 — 2015
Roche Glycart / Universitätsspital Basel / DBM, Schlieren and Basel, Switzerland
  • Assessment of novel tumor stroma-targeted IL-2-variant immunocytokines developped by Roche Glycart (mentor Dr. C. Klein), combined with anti-cancer therapeutics and immunomodulatory antibodies, in genetically engineered mouse models of non-small cell lung cancer
  • Collaborations with Prof. Dario Neri (ETHZ), Prof. M. Pittet (MGH), CureVac (mRNA cancer vaccine phase I), and VAXIMM
  • Deputy study director for animal licenses of the Cancer Immunology group (Prof. A. Zippelius)
IL-2 immunocytokines ICIs lung cancer LTK2 GEMM tumor xenografts co-culture IHC intratracheal SPECT/µCT animal licenses

Maître Assistant / Lab Manager

2008 — 2012
Ludwig Institute for Cancer Research / UNIL / CHUV, Lausanne, Switzerland
  • Characterization of CD8 T cell responses after therapeutic vaccination of melanoma patients with antigenic Melan-A/MART-1 peptides
  • Prospective phase I clinical trial from the group of Prof. P. Romero, Prof. D. Speiser and Dr. N. Rufer
  • Mentoring of students and technical staff
  • Collaboration with the Molecular Modelling group of Prof. O. Michielin
TCR tetramers flow cytometry sequencing RT-PCR microarray single cells cell sorting peptides PBMCs T cell cloning CTL ELISpot lentivirus

Visiting Scientist

2007 — 2008
Faculté de Médecine RTH Laennec, Lyon, France
  • Initiation of a national project on the transduction of human DCs with adenovirus and enhanced presentation of HIV-1 epitopes; applications to the potentiation of an anti-HIV-1 response
  • Continuation of a collaborative project started in Jan. 2006 with the Laboratory of Virology & Viral Pathogenesis (Prof. P. Boulanger)
HIV adenovirus dendritic cells molecular biology grant

Ph.D. Researcher

2003 — 2007
Université Louis Pasteur, Strasbourg, France
  • Development of innovative functional CD40L mimetics based on C3-symmetric peptide scaffolds, at the interface of chemistry and biology, and applications to cancer vaccines and immunotherapy
  • Lab manager in the Immunologie et Chimie Thérapeutiques (Prof. S. Müller), Institut de Biologie Moléculaire et Cellulaire (IBMC)
  • Mentoring of students and technical staff
apoptosis confocal microscopy SDS-PAGE Western blot 2D gel-electrophoresis ELISA hybridoma chromatography surface plasmon resonance dynamic light scattering organic chemistry mass spectroscopy

Teaching Assistant

2004 — 2007
Université Louis Pasteur, Strasbourg, France
  • Course assistant in immunology “travaux pratiques” for B.Sc. biochemistry, Université Strasbourg I
  • Teaching assistant in immunobiology “travaux dirigés” for first college degree in biology, Université Strasbourg I
immunology teaching

IT support

2004 — 2007
CNRS UPR9021, Université Louis Pasteur, Strasbourg, France
  • IT help to all my colleagues: installation of scientific software, workshops, hardware fix (with headache), network troubleshooting
  • Deployment and optimization of new hardware (computers and instruments)
Windows server peripherals network installation configuration maintenance troubleshooting

Competences and continuing education

Technical skills
Immunology
human PBMC Ficoll serum MACS T clones DCs MΦ 51Cr-release BATDA CTL lentivirus pMHC multimers ELISA ELISpot multiplex immunoassays

Cell biology
flow cytometry (Fortessa, Accuri, Calibur, Array, CyAn, Gallios, Attune) FACS (Ventage, Aria) imaging cytometry intracellular staining CBA transfection RNAi proliferation cell cycle apoptosis adherent suspension 3D-culture epifluorescence confocal microscopy time-lapse microscopy live imaging fluorescent IHC H&E staining cryosection AAV

Animal experimentation
injection (iv, sc, po, im, id, nas) intratracheal intrathoracic GEMMs tumor xenografts tumor growth survival blood sampling organ collection lymphoid tissues rodents genotyping SPECT/μCT (Bioscan) animal licenses

Molecular biology
(sc)RNA-Seq DNA/RNA isolation PCR ddPCR RT-PCR DNA sequencing TCR spectratyping molecular cloning recombinant proteins hybridoma insect cells Southern blotting Northern blotting functional promoter whole genome microarray (Agilent)

Biochemistry
SPR (BIAcore3000) DLS (Dynapro) SDS-PAGE Western blot 2D electrophoresis SEC peptide synthesis MS

IT skills

Professional development and training

Research output

Publications
  1. Young LE, Schnieke AE, McCreath KJ, Wieckowski S, Konfortova G, Fernandes K, Ptak G, Kind AJ, Wilmut I, Loi P, Feil R. Conservation of IGF2-H19 and IGF2R imprinting in sheep: effects of somatic cell nuclear transfer. Mech Dev (2003) 120:1433-1442. doi: 10.1016/j.mod.2003.09.006
  2. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, Gennaro R, Prato M, Bianco A. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl (2005) 44:6358-6362. doi: 10.1002/anie.200501613
  3. Wieckowski S, Fournel S, Sun W, Trouche N, Dumortier H, Bianco A, Chaloin O, Habib M, Peter JC, Schneider P, Vray B, Toes RE, Offringa R, Melief CJ, Hoebeke J, Guichard G. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol (2005) 1:377-382. doi: 10.1038/nchembio746 – Research Highlights: Drug Discovery: Immune booster. Nature (2005) 438:132. Immunotherapy: TNFR superfamily trimers. Nat Rev Drug Discov (2006) 5:1
  4. Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, Bianco A. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) (2006) 21:1182-1184. doi: 10.1039/b516309a – Recognized as within the top 50 articles published in 2006 in Chem Commun
  5. Bianco A, Fournel S, Wieckowski S, Hoebeke J, Guichard G. Solid-phase synthesis of CD40L mimetics. Org Biomol Chem (2006) 4:1461-1463. doi: 10.1039/b601528j
  6. Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotech (2007) 2:108-113. doi: 10.1038/nnano.2006.209
  7. Wieckowski S, Trouche N, Chaloin O, Guichard G, Fournel S, Hoebeke J. Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Biochem (2007) 46:3482-3493. doi: 10.1021/bi602434a
  8. Habib M, Chamekh M, Rivas MN, Wieckowski S, Sun W, Bianco A, Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray B. Small molecule CD40L mimetics promote control of parasitemia by enhancing CD8+ cells production of interferon-γ during experimental Trypanosoma cruzi infection. J Immunol (2007) 178:6700-6704. doi: 10.4049/jimmunol.178.11.6700
  9. Trouche N, Wieckowski S, Sun W, Chaloin O, Briand JP, Hoebeke J, Fournel S, Guichard G. Small trivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. JACS (2007) 129:13480-13492. doi: 10.1021/ja073169m
  10. Rich LR, Papalia GA, Flynn PJ… Wieckowski S… Myszka DG. A global benchmark study using affinity-based biosensors. Anal Biochem (2009) 386:194-216. doi: 10.1016/j.ab.2008.11.021
  11. Partidos CD, Hoebeke J, Wieckowski S, Chaloin O, Bianco A, Moreau E, Briand JP, Desgranges C, Muller S. Immunomodulatory consequences of ODN CpG-polycation complexes. Methods (2009) 49:328-333. doi: 10.1016/j.ymeth.2009.03.005
  12. Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P. Tumor antigen specific regulatory CD4 T-cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res (2009) 69:8085-8093. doi: 10.1158/0008-5472.CAN-09-2226
  13. Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero P, Speiser DE, Rufer N. Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol (2009) 183:5397-5406. doi: 10.4049/jimmunol.0901460
  14. Iancu EM, Baumgaertner P, Wieckowski S, Speiser DE, Rufer N. Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination. J Biomed Biotech (2011) 2011:452606. doi: 10.1155/2011/452606
  15. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplanke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest (2011) 121:2350-2360. doi: 10.1172/JCI46102
  16. Wieckowski S, Speiser DE, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero R, Rufer N. Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA (2011) 108:15318-15323. doi: 10.1073/pnas.1105419108
  17. Leimgruber A, Ferber M, Irving M, Wieckowski S, Hussain-Kahn H, Derré L, Rufer N, Zoete V, Michielin O. TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PloS ONE (2011) 6: e26301. doi: 10.1371/journal.pone.0026301
  18. Lövgren T, Baumgaertner P, Wieckowski S, Devêvre E, Guillaume P, Luescher I, Rufer N, Speiser DE. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination with low peptide dose. Cancer Immunol Immunother (2012) 61(6):817. doi: 10.1007/s00262-011-1140-1
  19. Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother (2012) 35(6):488. doi: 10.1097/CJI.0b013e31826183a7
  20. Wieckowski S, Hemmerle T, Savic Prince S, Dolder Schlienger B, Hillinger S, Neri D, Zippelius A. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung. Lung Cancer (2015) 88(1):9. doi: 10.1016/j.lungcan.2015.01.019
  21. Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, Rufer N. Quantitative TCR avidity assessment by NTAmers reveals melanoma antigen-specific T cell repertoires enriched for high functional competence. J Immunol (2015) 195:356. doi: 10.4049/jimmunol.1403145
  22. Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer H, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime – boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. OncoImmunology (2018) 7(4):e1303584. doi: 10.1080/2162402X.2017.1303584
  23. Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A. GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep (2019) 28(13):3367. doi: 10.1016/j.celrep.2019.08.057
  24. Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. Toward a better understanding of bioassays for the development of biopharmaceuticals by exploring the structure-antibody-dependent cellular cytotoxicity relationship in human primary cells. Front Immunol (2020) 11: 552596. doi: 10.3389/fimmu.2020.552596

Patents
  1. Guichard G, Fournel S, Chaloin O, Trouche N, Wieckowski S, Hoebeke J. Novel multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs. Brevet Français 04/13331, déposant CNRS (15/12/2004). International Application PCT/FR2005/03146 (15/12/2005). International Publication WO/2006/064133 (22/06/2006)
  2. Guichard G, Fournel S, Trouche N, Wieckowski S. Novel multimeric molecules, a process for preparing the same and the use thereof for manufacturing medical drugs. Brevet Français 07/00809, déposant CNRS (05/02/2007). International Application PCT/FR2008/000129 (04/02/2008). International Publication WO/2008/110695 (18/09/2008)

Communications (selection)
  • Wieckowski S, Avenal C, Orjalo AV, Gygax D, and Cymer F. A better understanding of bioassays – comparison of binding assays, reporter gene assays and primary cell-based assays of glycoengineered monoclonal antibodies. BEBPA’s Virtual 2021 EUR Bioassay Conference. Oral presentation
  • Wieckowski S, Podola L, Kobl I, Smetak H, Springer M, Nugues AL, Slos P, Broadmeadow A, Chesher C, Adda Berkane A, Wei M, Breiner K, Meichle A, Breiner K, Mansour M, Beckhove P, Lubenau H. Modulating T cell immunity in tumors by targeting tumor-associated antigens, PD-L1 and neoantigens using a versatile live attenuated oral Salmonella DNA vaccination platform. AACR Annual Meeting, Chicago, 2018. Poster 733
  • Wieckowski S. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium based oral T-cell vaccines. ASGCT 20th Annual Meeting, Washington DC, 2017. Oral presentation
  • Wieckowski S, Podola L, Springer M, Broadmeadow A, Stevens P, Chesher C, Adda Berkane A, Wei M, Kobl I, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety, immunogenicity and antitumor efficacy of live attenuated Salmonella Typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. AACR Annual Meeting, Washington DC, 2017. Poster 4558
  • Wieckowski S. Using the immune system to treat cancer – Could we cure cancer in the next ten years? European Health Science Match. Heidelberg, 2016. Oral presentation
  • Wieckowski S. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of- care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Basel, 2013. Oral presentation
  • Wieckowski S, Müller P, Freimoser-Grundschober A, Savic S, Fink Y, Karanikas V, Umana P, Pisa P, Klein C, Zippelius A. Therapeutic synergism of a novel tumor stroma-targeted IL-2-variant immunocytokine with standard-of-care anti-cancer therapeutics and immunomodulatory antibodies in the genetically engineered KP mouse model of non-small cell lung cancer. Roche Symposium of the Roche Postdoc Fellowship Program. Penzberg, 2012. Poster RPF ID 216
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Characterization of CD8+ T cell responses induced by vaccination with Melan-A peptides in melanoma patients. Role of Inflammation in Oncogenesis and Immune Escape in Cancer joint Keystone Symposia, Keystone, CO, 2010. Poster J5-338
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. Molecular characterization of CD8+ T cell responses in melanoma patients following therapeutic peptide vaccination. 4e Journée Scientifiques du Cancéropôle Lyon Auvergne Rhône-Alpes, Archamps (France), 2009. Poster P70. Best Poster Award (CLARA report)
  • Wieckowski S, Baumgaertner P, Corthésy P, Voelter V, Romero R, Speiser D, Rufer N. CD8 T cell responses in melanoma patients following therapeutic peptide vaccination. 1st Swiss Immunotherapy Symposium, Lausanne, 2009. Oral presentation
  • Wieckowski S, Trouche N, Hoebeke J, Guichard G, Fournel S. Application of functional small synthetic CD40L mimetics to lymphoma therapy. 1st joint meeting of European National Societies of Immunology, 16th European Congress of Immunology. Paris, 2006. Poster PD-3918
  • Wieckowski S, Trouche N, Sun W, Chaloin O, Hoebeke J, Guichard G, Fournel S. Improvements of small synthetic CD40L mimetics and their effects on cell signaling. MipTec – the 9th Leading European Drug Discovery Event. Basel, 2006. Poster P89
  • Wieckowski S, Trouche N, Chaloin O, Bianco A, Hoebeke J, Dumortier H, Guichard G, Fournel S. A synthetic multimeric ligand of CD40 is able to mimic effector functions of the natural CD40L. Congrès Annuel de la Société Française d’Immunologie. Paris, 2004. Poster P50

Congress abstracts
  • Wieckowski S, Podola L, Smetak H, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Beckhove P, Mansour M, Lubenau H. Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform. Cancer Res (2018) 78(13 Supplement):733-733
  • Wick W, Wick A, Sahm F, Riehl D, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Podola L, Herold-Mende C, Unterberg A, Platten MJ. VXM01 phase I study in patients with progressive glioblastoma: Final results. J Clin Oncol (2018) 36(15_suppl):2017-2017
  • Wieckowski S, Smetak H, Kobl I, Podola L, Nugues AL, Slos P, Berkane AA, Wei M, Breiner K, Meichle A, Mansour M, Schroff M, Beckhove P, Lubenau H. Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1. J Clin Oncol (2018) 36(5_suppl):74-74
  • Wieckowski S, Podola L, Springer M, Kobl I, Koob Z, Mignard C, Berkane AA, Wei M, Meichle A, Breiner K, Schroff M, Beckhove P, Lubenau H. Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Cancer Res (2017) 77(13S):Abstract nr 4558
  • Wick W, Wick A, Nowosielski M, Sahm F, Riehl D, Arzt M, von Deimling A, Bendszus M, Kickingereder P, Bonekamp D, Beckhove P, Schmitz-Winnenthal FH, Jungk C, Wieckowski S, Herold-Mende C, Lubenau H, Unterberg A, Platten MJ. VXM01 phase I study in patients with resectable progression of a glioblastoma. J Clin Oncol (2017) 35(15_suppl):2061-2061
  • Wieckowski S, Springer M, Podola L, Broadmeadow A, Stevens P, Chesher CJ, Berkane AA, Wei M, Meichle A, Beckhove P, Breiner K, Lubenau H. Non-clinical safety and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m. Eur J Cancer (2016) 69:S106
  • Guichard G, Trouche N, Wieckowski S, Sun W, Chaloin O, Bianco A, Hoebeke J, Schneider P, Fournel S. Rationally designed multivalent architectures for mimicking homotrimers of CD40L, a member of the TNF superfamily. Peptides for Youth: The Proceedings of the 20th American Peptide Symposium, Montreal (Canada), 2007. Adv Exp Med Biol (2009) 611:355-357

Peer-reviewing
Active reviewer in Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Journal of Cancer Research and Clinical Oncology, Cancers, Vaccines, Viruses, Biomedicines, Immuno, Journal of Clinical Medicine, Marine Drugs, Genes, Biomolecules, and International Journal of Molecular Sciences. See also records on ORCID and publons.